STAA vs. EYE, XRAY, MMSI, HAE, QDEL, NEOG, ICUI, ATRI, ANIK, and OSUR
Should you be buying STAAR Surgical stock or one of its competitors? The main competitors of STAAR Surgical include National Vision (EYE), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), QuidelOrtho (QDEL), Neogen (NEOG), ICU Medical (ICUI), Atrion (ATRI), Anika Therapeutics (ANIK), and OraSure Technologies (OSUR). These companies are all part of the "medical" sector.
STAAR Surgical (NASDAQ:STAA) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings.
96.7% of STAAR Surgical shares are owned by institutional investors. 1.0% of STAAR Surgical shares are owned by insiders. Comparatively, 2.3% of National Vision shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
STAAR Surgical has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, National Vision has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
In the previous week, National Vision had 8 more articles in the media than STAAR Surgical. MarketBeat recorded 13 mentions for National Vision and 5 mentions for STAAR Surgical. STAAR Surgical's average media sentiment score of 0.74 beat National Vision's score of 0.61 indicating that STAAR Surgical is being referred to more favorably in the media.
STAAR Surgical has a net margin of 4.69% compared to National Vision's net margin of -3.44%. STAAR Surgical's return on equity of 6.83% beat National Vision's return on equity.
STAAR Surgical has higher earnings, but lower revenue than National Vision. National Vision is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.
STAAR Surgical presently has a consensus price target of $47.13, suggesting a potential upside of 13.47%. National Vision has a consensus price target of $19.60, suggesting a potential upside of 29.89%. Given National Vision's higher possible upside, analysts clearly believe National Vision is more favorable than STAAR Surgical.
STAAR Surgical received 32 more outperform votes than National Vision when rated by MarketBeat users. However, 65.89% of users gave National Vision an outperform vote while only 56.10% of users gave STAAR Surgical an outperform vote.
Summary
STAAR Surgical beats National Vision on 12 of the 18 factors compared between the two stocks.
Get STAAR Surgical News Delivered to You Automatically
Sign up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
STAAR Surgical Competitors List
Related Companies and Tools